Tosoh Bioscience, Inc. has announced that calibration curve stability for most Tosoh AIA assays has been extended to 90 days. Improved calibration curve stability is made possible through Tosoh’s AIA-Pack Unit Dose Test Cup reagent technology.
Tosoh’s AIA-PACK test cups are single, unitized cups that utilize a dry reagent format which requires no pre-mixing, no pre-measuring, no on-board refrigeration and no waste. The test cup format is used on all Tosoh AIA automated immunoassay analyzers, including the AIA-2000 (200 tests per hour), AIA-1800 (180 tests per hour), AIA-600 II (60 tests per hour), and AIA-360 (36 tests per hour).
Calibration is an extremely important step in immunoassay testing as the value reported is a quantitative estimate of concentration by direct comparison with a calibrator material. The aim of calibration is to improve the accuracy. Reducing the frequency of calibration helps laboratories to reduce overall costs and technician time.
Tosoh’s extensive immunoassay test menu provides a wide range of immunoassay tests including thyroid, cardiac markers, tumor markers, reproductive hormones, anemia markers, metabolic markers and more. All Tosoh AIA-PACK assays now carry 90 day calibration curve stability with the exception of Troponin I, B12 and Folate, which will continue to have the 30 day calibration stability.
AIA-PACK test cups and trays are labeled with code and lot number for automated scheduling and inventory management. A 10 minute incubation protocol provides fast turnaround time. Additionally Tosoh AIA reagents have a shelf life of 1 year from the date of manufacture.
Because AIA-PACK test cup reagents are interchangeable on all Tosoh AIA systems, inventory management is easy and problem free. Transition from one system to another is seamless, ensuring consistent results and efficient, economical operation for the laboratory.
Tosoh Bioscience, Inc. (TBI) provides highly sophisticated diagnostic systems for immunoassay and HPLC testing to doctor’s offices, hospitals and reference laboratories throughout the Americas. Based in South San Francisco, CA, TBI is a U.S. subsidiary of Tosoh Corporation’s Bioscience Division, headquartered in Tokyo, Japan.